Merck's Keytruda Under Pressure from New Lung Cancer Competitor

The recent Phase 3 survival data showing ivonescimab outperformed Keytruda in lung cancer treatment is altering the investment case for Merck (MRK). The mix of fresh competitive oncology data against Keytruda and Merck's own partnership and pipeline activity highlights how the group's long-term cancer revenue mix and investment priorities may need to adjust over time.

The investment narrative for Merck requires it to turn its broad pipeline and recent launches into enough cash flow to soften future Keytruda exclusivity risk and pricing pressure. This includes executing on forecast earnings growth, a rich late-stage portfolio, and heavy manufacturing spend to achieve cleaner margins after recent one-off hits.

The clinical trial collaboration with Perspective Therapeutics is most relevant in this context. Merck is supplying Keytruda to test it alongside [212Pb]PSV359 in FAP-a expressing non-small cell lung and colorectal cancers. The trial has already completed enrollment in the first three monotherapy dose cohorts, so the combination arm slots into an ongoing program rather than starting from scratch.